Edmonton, Alberta, Canada/May 31, 2023- Pacylex Pharmaceuticals, a clinical-stage company developing PCLX-001, a first-in-class oral investigational small molecule for leukemia, lymphoma, and solid tumor cancers, today announced that it will be attending the Biotechnology Innovation Organization (BIO) International Convention taking place June 5-8, 2023, at the Boston Convention & Exhibition Center, in Boston, Massachusetts, USA. The BIO Convention is the premier life sciences networking conference in the world, bringing together leaders, innovators and investors from the pharmaceutical, biotech and medical device industries.
Pacylex’s Chief Executive Officer, Dr. Michael Weickert, will be attending the conference and participating in the BIO One-on-One Partnering™ system. He will be available to share Pacylex’s recent clinical progress with PCLX-001, including the initiation of a Phase 2a study in patients with B-cell Non-Hodgkin Lymphoma last month, and discuss investment and licensing options. “We are looking forward to discussing our progress on the PCLX-001 clinical development program with potential investors and partners at BIO,” said CEO Michael Weickert.
Registered attendees can schedule a meeting with Dr. Weickert using the BIO One-on-One Partnering™ system. If there are no compatible time slots available, please contact Dr. Weickert directly to schedule a meeting.
PCLX-001 is a first-in-class, oral, small molecule N-myristoyltransferase (NMT) inhibitor being developed to treat patients with leukemia and lymphoma. PCLX-001 selectively kills cancer cells in vitro and has been shown to regress hematologic malignancies and inhibit the growth of lung and breast cancer tumors in animal models. PCLX-001 appears to be particularly effective against Acute Myeloid Leukemia (AML) stem cells in animal disease models.
The Phase 1/2a study (NCT04836195) is an open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of PCLX-001 in patients with R/R NHL and advanced solid malignancies who have progressed on all available standard therapies.
About Pacylex Pharmaceuticals
Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with a first-in-class, oral, once-daily investigational therapeutic, PCLX-001. Pacylex has a US Subsidiary in the San Francisco Bay area. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex is conducting a multi-center Phase 1 multiple ascending dose study in Canada in patients with R/R NHL and advanced solid tumors, and a Phase 2a dose expansion in patients with R/R NHL. The US Department of Defense is supporting the initial clinical investigation of PCLX-001 in patients with AML. The FDA has granted PCLX-001 both Orphan Drug Designation and Fast Track Designation for AML. Pacylex received support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation.
Pacylex Pharmaceuticals: Michael J. Weickert
CEO, Pacylex Pharmaceuticals, Inc.
#cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta, #MDACC, #BIO2023